S. 2699 · 109th Congress
Elimination of Neglected Diseases Act of 2006
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 109th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BrownbackSponsor1 cosponsor · 1 D
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Elimination of Neglected Diseases Act of 2006 - Provides for the extension and restoration of the patent term for a certified tropical disease product: (1) that is used to treat neglected or tropical diseases such as HIV, malaria, tuberculosis, or other infectious disease that disproportionately affect poor and marginalized populations; and (2) the patent…
What it does: CRS summary · Introduced in Senate · May 2, 2006
Elimination of Neglected Diseases Act of 2006 - Provides for the extension and restoration of the patent term for a certified tropical disease product: (1) that is used to treat neglected or tropical diseases such as HIV, malaria, tuberculosis, or other infectious disease that disproportionately affect poor and marginalized populations; and (2) the patent for which claims an approved new molecular entity standard review drug or the process of making such a drug or the drug's active ingredient.
Requires the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to: (1) designate as a new molecular entity standard review drug a drug that has a new molecular entity chemical type classification and standard review drug treatment potential classifications and is not a drug developed to treat serious or life-threatening diseases; and (2) maintain and annually update a classification list of serious and life-threatening diseases. Allows the Secretary, acting through the Commissioner, to remove the designation of a drug as a new molecular entity standard review drug.
Requires the Director of the United States Patent and Trademark Office (USPTO) to study the effect of patent extension and restoration on the ability of pharmaceutical companies to develop and distribute tropical disease products for poor and marginalized populations.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Elimination of Neglected Diseases Act of 2006
Latest action (May 2, 2006): Read twice and referred to the Committee on the Judiciary.
Policy area: Commerce · Origin: Senate · Introduced: May 2, 2006
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.